Darunavir and Cobicistat

Therapeutic indications

Darunavir and Cobicistat is indicated for:

Human immunodeficiency virus-1 infection

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Darunavir/cobicistat fixed dose combination is indicated, in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg).

Genotypic testing should guide the use of darunavir/cobicistat.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Darunavir and Cobicistat is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Severe hepatic impairment

Hepatic failure stage IV

Strong CYP3A inducers

at least one of
Strong potency CYP3A4 inducers
Cytochrome P-450 CYP3A5 strong inducers
Hypericum perforatum (St John's Wort)
Carbamazepine
Phenytoin
Lopinavir and ritonavir
Lopinavir and additionally Ritonavir

Astemizole, terfenadine

at least one of
Astemizole
Terfenadine

Rifampicin

Rifampicin

Ergot derivatives

at least one of
Ergotamine
Ergot alkaloids
Selective serotonin (5HT1) agonists

Cisapride

Cisapride

Nevirapine

Nevirapine

Efavirenz

Efavirenz

Etravirine

Etravirine

Bosentan

Bosentan

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.